Transcode Pays $841K to Yorkville to Waive Amortization Trigger on Convertible Notes
RNAZ is trading near its 52-week low of $1.52 (1.6% above the low) on light trading volume (0.3× avg).
Summary
Transcode paid Yorkville $840,975 to waive an Amortization Event triggered when its stock traded below the $1.72 floor price for 10 of 14 days. The waiver lasts through October 31, but the stock remains near its 52-week low, making a new trigger likely.
Key Events · Financing and Capital Events · RNAZ
-
Amortization Event Triggered
Daily VWAP fell below the $1.72 floor price for 10 of 14 trading days from September 11 to September 30, 2026, triggering an Amortization Event under the Yorkville Convertible Notes.
-
Waiver Secured with $841K Prepayment
On October 1, 2026, Transcode paid $840,975 to Yorkville — $759,000 principal, $75,900 prepayment premium, and $6,075 accrued interest — in exchange for waiving the Amortization Event through October 31, 2026.
-
Principal Reduced to $4.1M
After the prepayment, approximately $4.1 million in principal remains outstanding under the Convertible Notes.
-
Cash Runway Pressure
The prepayment consumes a meaningful portion of the $8.4 million cash balance reported August 14, 2026, with a going concern warning and runway only through year-end 2026.
Analysis · RNAZ · Life Sciences
A forced amortization schedule on its Yorkville convertible notes was avoided by Transcode Therapeutics through an $840,975 prepayment made on October 1, 2026. The trigger was a decline in the stock's daily VWAP below the $1.72 floor price for 10 of 14 trading days, which would have required monthly payments of 18% of outstanding principal plus a 10% premium and accrued interest. The waiver extends through October 31, 2026, buying the company roughly one month of breathing room, but the underlying problem remains: the stock trades near its 52-week low at $1.545, well below the floor price, so a new Amortization Event is likely unless the share price recovers above $1.72 for 10 consecutive trading days. With only $8.4 million in cash as of August 14 and a going concern warning, this prepayment consumes a meaningful portion of remaining liquidity while leaving $4.1 million in principal outstanding.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.2% of the 1513 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNAZ was trading at $1.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.2M. The 52-week trading range was $1.52 to $20.99. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.